Leaflet MOXIFLOXACINA KABI 400mg / 250ml solution for infusion


Indicated for: bacterial infections

Substance: moxifloxacin (fluoroquinolone antibiotic)

ATC: J01MA14 (Antiinfectives for systemic use | Quinolone antibacterials | Fluoroquinolones)

Moxifloxacinum is a fluoroquinolone antibiotic used to treat bacterial infections, including respiratory infections, sinusitis, skin infections, and intra-abdominal infections. It works by inhibiting bacterial enzymes essential for DNA replication, thereby killing the bacteria.

The medication is administered orally or intravenously, depending on the severity of the infection. It is effective against a wide range of bacteria, including strains resistant to other antibiotics.

Side effects may include nausea, diarrhea, dizziness, and, in rare cases, severe reactions such as tendinitis or tendon rupture. It is important to inform your doctor about any side effects or other medications you are taking.

Consult your doctor before use, especially if you have liver, kidney, or other health conditions. Use Moxifloxacinum as directed to prevent the development of bacterial resistance.

General data about MOXIFLOXACINA KABI 400mg / 250ml

  • Substance: moxifloxacin
  • Date of last drug list: 01-05-2026
  • Commercial code: W60727002
  • Concentration: 400mg / 250ml
  • Pharmaceutical form: solution for infusion
  • Quantity: 10
  • Product type: generic
  • Price: 719.68 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: FRESENIUS KABI POLSKA SP. Z.O.O. - POLONIA
  • Holder: FRESENIUS KABI ROMANIA S.R.L. - ROMANIA
  • Number: 11511/2019/02
  • Shelf life: 3 years-after packing for marketing;after the first opening- se utilizeaza imdiat

Pharmaceutical forms available for moxifloxacin

Concentrations available for moxifloxacin

  • 400mg
  • 400mg/250ml
  • 5mg/ml

Compensation lists for MOXIFLOXACINA KABI 400mg / 250ml Fresenius

NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment

Price

Copayment

Patient

719.68 RON

719.68 RON

0.00 RON

NHP 1.B (C2) - Tuberculosis

Price

Copayment

Patient

719.68 RON

719.68 RON

0.00 RON